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Background: Hepatitis C virus infection is a serious public health problem. Hemodialysis is considered one of the
main risk factors of HCV infection, due to several invasive medical procedures and potential nosocomial
transmission that patients with chronic renal failure (CRF) are continuously submitted. The aims of this study were
to determine the prevalence of HCV and its genotypes in patients with CRF in hemodialysis units in southern Brazil.
Methods: Demographic data and risk factors for HCV transmission were collected and analyzed. These data were
obtained from patients undergoing hemodialysis treatment from January 2009 to August 2010, on two dialysis
units of Rio Grande, southern Brazil. Genotyping was carried out by sequencing analysis of HCV NS5b, core-E1
junction and 5′UTR genomic regions.
Results: One hundred fifty-nine patients under regular hemodialysis treatment were studied. HCV prevalence was
23.3%. HCV-infected patients had been on dialysis treatment for 91.9 months, a more prolonged period compared
to HCV-negative patients (p = 0.001). While HCV genotypes 1b and 3a were identified as the most frequent strains,
a surprisingly high proportion of genotype 2b was observed among patients in one of the dialysis centers
compared to the general HCV-infected population of the same area. Hemodialysis treatment exposure time and
healthcare working were associated with HCV infection.
Conclusions: Besides the efforts to minimize nosocomial transmission of HCV, some events of transmission are still
evidenced in dialysis units.
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Approximately 170 million people worldwide are infected
with the hepatitis C virus (HCV) and are at risk of de-
veloping chronic hepatitis, cirrhosis and hepatocellular
carcinoma [1,2]. Moreover, HCV infection is the most
common indication for liver transplantation in developed
countries [3].
Brazil has an intermediate prevalence of hepatitis C,
varying from 2.5% to 10% [4]. Recently, a nationwide
and comprehensive cross-sectional, population-based* Correspondence: masoares@inca.gov.br
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reproduction in any medium, provided the orsurvey has reported an HCV seropositivity rate of 1.38%
[5]. Nevertheless, in the southern region of the country,
anti-HCV positive confirmed cases are higher than the
national average (9.4 versus 5.4 per 100,000 subjects in
2011, respectively) [6].
Hemodialysis is considered one of the major risk fac-
tors for HCV infection, due to numerous vascular access
procedures, periodic blood transfusions and potential
nosocomial transmission to which patients with chronic
renal failure (CRF) are continuously subjected [1,7]. In
spite of effective control and safe medical practices im-
plemented to reduce the risk for transmission of infec-
tious diseases among hemodialysis patients, sporadic
outbreaks in dialysis units still occur. The major proce-
dures to prevent HCV nosocomial transmission includel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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use of erythropoietin to minimize blood transfusions [7,8].
Some factors, such as blood transfusions and duration of
hemodialysis treatment, have been particularly related to a
higher mortality rate among those patients [9-13].
HCV infection varies by patient characteristics, geo-
graphic location, socioeconomic aspects, number of pa-
tients per dialyzer and rigorous use of the strictest
biosafety standards [14,15]. Differences in patient behav-
ior and community exposure factors may also contribute
to the higher prevalence of HCV in hemodialysis units
[15]. HCV prevalence among Brazilian hemodialysis pa-
tients ranges from 11% to 90% but HCV genotype
characterization is not well documented [16-21]. HCV
genotype 1a is the most prevalent, followed by 1b and 3a
[21-25], except for the study by Busek and colleagues [20]
who found genotype 2b as the second most prevalent.
Chronic renal patients have particular features that im-
pair HCV diagnostics. Slight increases in aminotransferases
levels, intermittent viremia and negative anti-HCV serology
for a long period after infection are characteristics com-
monly observed in this population [7,19]. HCV RNA de-
tection by RT-PCR is the best method to diagnose HCV
infection in patients with CRF [26,27], despite the intermit-
tent viremia described in 33% to 67% of anti-HCV positive
patients [7].
The aims of this study were to determine the preva-
lence of HCV and its genotypes in patients with CRF in
two hemodialysis centers of Rio Grande, southern Brazil,
and the main risk factors associated with infection in
this patient group.
Results
The population analyzed comprised 57.2% of males, the
mean age was 56.9 years (SD ± 15.9), and 65.4% were
Caucasians. With respect to education, 66.7% were illit-
erate or had not completed elementary school. The main
reported risk behaviors for HCV were blood transfusion
(94.3%) and surgical procedures (90%). Approximately 2%
of the patients reported hemophilia, 2% were intravenous
drugs users (IDU), 3% shared syringes or needles and 2%
informed use of inhaled cocaine.
HCV prevalence in the analyzed dialysis units was
23.3% (37/159). The mean age among HCV positive pa-
tients was 54.9 years (SD ± 13.3) and 62.2% were male.
The statistical model for HCV infection was adjusted for
age. Table 1 shows the crude and adjusted PRs for HCV
infection according to HCV risk factors. As observed,
the multivariate analysis revealed a significant PR for
healthcare workers of 4.26 (p = 0.048).
The average time of hemodialysis among all patients en-
rolled in this study was 55.1 months (SD ± 58). By contrast,
HCV-positive patients had been on dialysis treatment for
92 months (SD ± 82), a time period significantly higher ifcompared to HCV-negative patients (44 ± 43 months;
p = 0.001). In the multivariate analysis depicted in Table 1,
this variable also showed borderline significance (p = 0.09)
as independently associated with HCV infection. Whereas
pre- and post-dialysis urea, potassium, calcium and phos-
phorus levels did not differ between HCV-negative and
positive patients (data not shown), mean serum alanine
aminotransferase (ALT) was significantly higher among in-
fected patients (17.1 versus 27.6 IU/L; p = 0.003), an ex-
pected finding.
All serological results were confirmed by HCV RNA
detection followed by PCR of NS5b or 5′UTR (Table 2).
HCV genotyping was carried out in 31 (84%) of the in-
fected patients, based on phylogenetic analysis of NS5b
sequences. In six cases, HCV subtyping was not possible
due to negative PCR results for this viral genomic region.
These comprised four genotype 1 strains, one genotype 2
and one genotype 3. Overall, 33 5′UTR and 31 NS5b
sequences were determined. For isolates for which both
NS5b and 5′UTR sequences were available, both regions
revealed the same genotype in all cases. According to the
analysis of NS5b region, 14 belonged to genotype 1; four
were subtype 1a (13%) and 10 were subtype 1b (32.5%).
All genotype 2 isolates (n = 7) belonged to subtype 2b,
with a prevalence of 22%. HCV genotype 3 (subtype 3a),
was also present in 10 subjects (32.5%). All genotypic clas-
sifications were further confirmed by HCV 5′UTR se-
quencing (data not shown). A single additional genotype
2b isolated was found in Unit 1, for which only the 5′UTR
genomic region was available. Figure 1A depicts all HCV
NS5b fragments phylogenetically analyzed. It is evident
from the tree that all genotype 2b isolates characterized in
this work (all from Unit 2) clustered together, although
only a fairly significant bootstrap value was achieved
(70%). This cluster is not observed for the remaining ge-
notypes found (Figure 1A), for which the sequences are
interleaved with database reference sequences. However,
some subtype 1a and 1b sequences are strongly similar in
the analyses, and a common source of transmission in
those cases cannot be completely ruled out.
In order to corroborate the existence of a transmission
cluster harboring the HCV subtype 2b sequences in Unit 2,
phylogenetic analysis of another HCV genomic region (the
core-E1 boundary) was carried out. A semi-nested PCR of
that region was attempted for five out of the seven HCV-
2b viruses observed in Unit 1, and of those four E1 se-
quences were generated. As shown in Figure 1B, the four
sequences still clustered together with a bootstrap value
of 80%, further highlighting the transmission cluster seen
with NS5b sequences.
Discussion
This is the first study characterizing the prevalence of
HCV genotypes among patients undergoing hemodialysis
Table 2 HCV subtype distribution in patients under
hemodialysis according to phyogenetic analysis of the
5′UTR and NS5b genomic regions
Region/Subtype N
Total (%) Unit 1 Unit 2
5′UTR*
1a 17 (52) 5 12
1b
2b 6 (18) 1 5
3a 10 (30) 1 9
NS5b
1a 4 (13) 0 4
1b 10 (32.5) 3 7
2b 7 (22) 0 7
3a 10 (32.5) 0 10
* For genotype 1, 5′UTR does not distinguish subtypes, and numbers
are combined.
Table 1 Crude (cPR) and adjusted (aPR) prevalence ratios for HCV infection according to risk factors (n = 159)
Characteristic Frequency total Frequency HCV+ cPR (95% CI) p aPR (95% CI) p
Age (years) - - 0.98 (0.97 – 1.07) 0.32 0.98 (0.97 – 1.00) 0.19
Sex 1.23 (0.68 – 2.21) 0.5 1.19 (0.67 – 2.16) 0.53
Male 57.2 62.2
Female 42.8 37.8
Education 0.71 (0.37 – 1.39) 0.32 0.64 (0.34 – 1.21) 0.18
≤ 11 years 89.9 94.6
≥ 12 years 10.1 5.4
Surgery 0.92 (0.37- 2.27) 0.87 0.86 (0.35 – 2.11) 0.73
Yes 89.9 89.2
No 10.1 10.8
Blood Transfusion 2.16 (0.33-14.09) 0.42 1.93 (0.32- 11.56) 0.47
Yes 94.3 97.3
No 5.7 2.7
Tattoo and piercing 0.60 (0.09- 3.80) 0.59 0.47 (0.12- 1.81) 0.27
Yes 4.4 2.7
No 95.6 97.3
Healthcare work 2.71 (1.24- 5.91) 0.01 2.97 (1.31- 6.75) 0.009
Yes 3.1 8.1
No 96.9 91.9
Injection and inhaled drug use 1.44 (0.28 - 7.37) 0.66 2.69 (0.18- 38.31) 0.46
Yes 1.9 2.7
No 98.1 97.3
Syringe sharing 1.76 (0.57 - 5.37) 0.32 0.75 (0.11- 4.93) 0.76
Yes 3.1 5.4
No 96.9 94.6
Time of hemodialysis (mo.) - - 0.99 (0.98 - 1.00) 0.23 0.99 (0.99 - 1.00) 0.09
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type 2b has been found, a genotype with rare occurrence
in Brazil, what suggests a possible nosocomial transmis-
sion event in one of the two hemodialysis units studied
herein. Nosocomial transmission is still a common event
in dialysis units, and the proper detection of HCV infec-
tion among these patients remains a challenge.
The HCV infection prevalence found in this study
(23.3%) was higher compared to previous studies in gen-
eral population at the same region, which reports preva-
lence of 6% to 8.6% [28]. On the other hand, when studies
conducted with patients on hemodialysis are considered,
HCV prevalence of 14.6% to 46.7% have been reported in
different Brazilian cities [16,17,19,20]. This discrepancy
largely highlights HCV as a major morbidity in hemo-
dialysis units, jeopardizing the safety of patients with CRF.
In this study, hemodialysis treatment time and health-
care occupation were significantly associated with HCV
infection, the majority of them occurring in older adults






















































































































Figure 1 Phylogenetic tree depicting the HCV NS5b (A) or the core-E1 junction (B) genomic region of the analyzed isolates. HCV isolates
characterized in the study are highlighted with symbols (circle, subtype 1b; square, subtype 1a; diamonds, subtype 2b; triangles, subtype 3a).
Only bootstrap support values above 80% are shown, which differentiate major HCV genotypes and subtypes. The tree was rooted with a
subtype 7a sequence, a variant not found in Brazil. Bars below the trees represents a genetic distance of 5% at the nucleotide level.
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treatment.
Several geographic and ethnic differences in the preva-
lence of HCV genotypes, as well as temporal, behavioral
and cultural differences, have been reported [30,31]. While
in Brazil HCV genotypes 1 and 3 are predominant, in some
Latin American countries, like Argentina and Venezuela,
genotypes 1 and 2 prevail, responding for approximately
90% of the cases [32]. In Europe, a continuous decrease of
genotype 3 is observed, and an increase of genotype 2 has
been registered [33,34]. The HCV genotype distribution in
this study was similar to those reported by other authors
for the same geographic region, with HCV genotypes 1 and3 being responsible for most infections [35-37]. Genotype
3a has been reported as particularly common in southern
Brazil [36,38]. Noteworthy, however, is the high prevalence
of genotype 2b among the patients treated in the hemo-
dialysis units enrolled here, especially from one of the units
studied. This is a unique characteristic, considering the
low prevalence of this genotype in Brazil [15,21,33,39,40].
These findings suggest a potential role of nosocomial
transmission among the patients involved.
Hepatitis C is the most common cause of chronic viral
liver disease in haemodialysis patients [17]. Several risk
factors for HCV acquisition have been identified among
these patients, including surgery and frequent blood
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mial transmission in the dialysis units may be associated
with hemodialysis procedures, such as aerosol formation
during fistula cannulation for vein access, accidents with
contaminated blood and direct contact with contaminated
materials used by infected patients [41].
Our hypothesis of nosocomial transmission of HCV
genotype 2 is also supported by the phylogenetic analysis
of the characterized isolates. All subtype 2b sequences
clustered together for two distinct HCV genomic regions
analyzed, suggesting a common source of infection. This
feature was not seen for the other genotypes studied,
where database reference sequences intermingled with
query sequences, except for a few potential transmission
links within the subtype clades. On the other hand, it is
likely that subtype 2b circulates in Brazil as a monophy-
letic lineage, based on recent nationwide HCV sequence
analyses (Lampe et al., Antivir Ther in press). Therefore,
we cannot exclude the possibility that the subtype 2b
cluster seen here reflects such single introduction of this
subtype in the country, rather than a bonafide intra-unit
dissemination. However, epidemiological data regarding
the frequency of this subtype in Brazil largely argues in
favor of the nosocomial transmission hypothesis. Yet this
is the likely scenario in the analyzed setting, one cannot
completely rule out the additional possibility that the
genetic background of this variant facilitates its paren-
teral transmission. Paraboni and colleagues [26] found
an association of HCV genotype 2b with dental proce-
dures in southern Brazil. Added to this factor, other as-
pects associated to CRF patients may also be considered
to explain the higher prevalence of genotype 2b, and its
facilitated transmission among medical or dental inter-
ventions. Finally, yet genotype 2b is not a common variant
in Brazil, it is a very prevalent genotype in neighboring
countries of its southern boundaries, like Argentina, with
which Brazil has an intense population interflow. Such
scenario may also contribute to the higher prevalence of
genotype 2b in the area.
The Brazilian Public Health System has established
guidelines to prevent the spread of HCV in dialysis units
[42]. These actions included rigorous implementation of
universal precautions and biosafety procedures, screening
for anti-HCV among patients, sterilization of dialysis ma-
chines and all instruments used and training of healthcare
workers. Another important measure implemented is the
isolation of patients with positive serology for anti-HCV,
even during their transport or transfer, because of the risk
of vascular bleeding due to heparinization during dialysis
[2,15,43]. Under this scenario, it is important to know the
serological status of all patients in the unit, so that mea-
sures can be implemented successfully. The difficulties on
diagnosing HCV infection on CRF patients constitute the
major limitation against the efforts to avoid nosocomialtransmission on dialysis units. Due to late seroconversion
on these patients, serological testing alone is inconclusive
for HCV screening, generating false negative results
[19,26,44,45].
Conclusions
In conclusion, it has been extensively discussed that pa-
tients on hemodialysis treatment are at high risk for
HCV infection. Besides the efforts to minimize or elim-
inate nosocomial transmission of HCV, some events can
still be detected in different dialysis units. It is important
to consider HCV RNA measurement in these patients,
because the immunosuppression inherent to chronic
renal disease, as a preventive factor against nosocomial
spread of HCV.
Methods
Patients and study design
This was a prospective study, developed among patients
undergoing hemodialysis treatment from January 2009
to August 2010, followed at two dialysis units located in
the city of Rio Grande, southern Brazil. One hundred
and fifty nine patients were enrolled in this survey, 116
from Unit 1 and 43 from Unit 2. The study was conducted
with the approval of the local Ethics Committee of the
Federal University of Rio Grande (number 7222741/2008).
Written informed consent was obtained from all patients,
and eligibility criteria included age over 17 years and agree-
ment to answer a standardized questionnaire containing
sociodemographic variables as well as information on risk
behaviors and practices relevant to HCV acquisition.
Samples
HCV serology, alanine aminotransferase levels and other
biochemical variables were carried out at the dialysis units.
Both units performed HCV screening on their patients peri-
odically, on a quarterly basis, by a third-generation anti-
HCV ELISA (Imuno-Elisa Anti-HCV, Wamma Diagnóstica,
São Paulo, Brazil). During serological screening, one ad-
ditional sample of 5 mL of whole blood was collected into
an ethylenediamine tetraacetic acid tube from each patient
enrolled in the study. Plasma was separated and sent to the
Laboratory of Molecular Biology of Universidade Federal
do Rio Grande (FURG) and stored at −80°C. HCV-positive
samples (n = 37) were thawed and analyzed for HCV RNA
detection and genotyping.
Determination of HCV RNA and HCV genotype
Viral RNA was extracted from 140 μL of plasma with the
QIAamp Viral RNA extraction kit (Qiagen, Chatsworth,
USA). A final volume of 60 μL of viral RNA was mixed
with 600 ng of random primers (Life Technologies,
Carlsbad, USA) in diethylpyrocarbonate-treated water and
incubated for 10 min at 70°C. Reverse transcription was
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Virus reverse transcriptase (Life Technologies, Carlsbad,
U.S.A.), 0.1 mol/L DTT, 25 U of RNaseOUT (Life Tech-
nologies) and 0.5 mmol/L of each deoxynucleotide for
90 minutes at 37°C. A semi-nested polymerase chain reac-
tion (PCR) assay was conducted with the primers Pr3 (5′-
TATGAYACCCGCTGYTTTGACTC-3′; outer foward),
Pr4 (5′-GCNGARTAYCTVGTCATAGCCTC-3′; inner
foward) and Pr5 (5′-GCTAGTCATAGCCTCCGT-3′; re-
verse) to amplify a 380 bp product corresponding to an in-
ternal region of HCV NS5b gene [46]. Additional nested
PCR assays were performed with primers PTC1 (5′CGT
TAGTATGAGTGTCGTGC3′) and NCR2 (5′ATACTCG
AGGTGCACGGTCTACGAGACCT3′) in the first round,
and with PTC3 (5′GTGTCGTGCAGCCTCCAGG3′) and
NCR4 (5′CACTCTCGAGCACCC TATCAGGCAGT3′)
in the second round, to amplify a 220 bp product corre-
sponding to a region of HCV 5′UTR (Campiotto et al.,
2005). Finally, for a subset of HCV subtype 2b (see Re-
sults), another semi-nested PCR reaction was carried out
for amplifying a 470 bp viral genomic fragment spanning
the end of the core and the beginning of the E1 genes,
using the primers E1-Fow (5′GGCGTCGGTGTYAGRG
TYCTGG3′), E1-1stRev (5′GGCRGTCCGRTTTATGTG
CC3′) and E1-2ndRev (5′ATGACYTTGGCCCACGC
TCC3′). PCR products were analyzed by electrophoresis
through a 1.5% agarose gel stained with ethidium bromide.
PCR products were sequenced using the Big Dye v.3.1
kit in an ABI 3130XL Genetic Analyzer (both from Life
Technologies). Sequences were manually edited with
SeqMan v7.0 (DNASTAR Inc., Madison, USA) and aligned
with BioEdit v.7.02316 along with HCV reference se-
quences from the Los Alamos National Laboratory HCV
Database (http://hcv.lanl.gov). Genotypes were determined
through phylogenetic inference using neighbor-joining and
Kimura’s two-parameter, with 1000 bootstrap replicates, in
MEGA 5.
All NS5b DNA sequences generated in this study have
been deposited in GenBank and were assigned the numbers
[GenBank: JQ711195-JQ711198, KC520829-KC520855]. 5′
UTR sequences have not been deposited because they are
shorter than 200 bp, a sine qua non condition for submis-
sion to the GenBank database.
Statistical analyses
All analyses were performed with STATA® v. 8.0 (Stata
Corporation, 2009). The association of time on dialysis in
months and HCV infection was assessed by a Student’s
t test. HCV prevalence and 95% confidence intervals (CIs)
were estimated. Bivariate analysis was performed for calcu-
lating the prevalence ratios and CIs of several factors and
outcomes. In order to adjust for potential confounders, a
multivariate analysis was performed using Poisson regres-
sion and prevalence ratios (PRs) were determined.Competing interests
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